Who is sponsoring NCT01413763?

NCT01413763 is sponsored by Medicis Global Service Corporation.

What condition does NCT01413763 study?

NCT01413763 studies Actinic Keratosis.

What drugs are being tested in NCT01413763?

Interventions: Imiquimod cream 3.75%, Placebo cream.

What is the status of NCT01413763?

NCT01413763 is currently UNKNOWN.

Last reviewed 2012-10-24 · How we verify

A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis

NCT01413763 Phase 4 UNKNOWN

The purpose of this study is to determine the potential effect of topically applied 3.75% imiquimod cream on atrial ectopy in actinic keratosis (AK) patients. The primary endpoint is the change in the 24-hour supraventricular premature beat count. The secondary endpoint is the change in 24-hour supraventricular premature couplet and run counts and atrial fibrillation (% time); change in 24-hour mean heart rate; change in 24-hour ventricular premature beat count, ventricular premature couplet and run counts.

Details

Lead sponsor	Medicis Global Service Corporation
Phase	Phase 4
Status	UNKNOWN
Enrolment	50
Start date	2011-07
Completion	2013-04

Conditions

Actinic Keratosis

Interventions

Imiquimod cream 3.75%
Placebo cream

Primary outcomes

Change in 24-hour supraventricular beat count — Day 14 of each treatment period

Countries

United States